Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Old API Wind-down Ltd - Ordinary Shares > Bought more
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(44)
•••
Comment by snootchybootchyon May 06, 2016 3:52pm
111 Views
Post# 24849289

RE:RE:Bought more

RE:RE:Bought more
kuatolives wrote: Yeah I've started accumulating again as well. We're now at something like 4x earnings without Yosprala which could quadruple earnings in a few years. Getting cheap enough I don't mind throwing some more money at it.  The market is behaving quite irrationally to the biotech industry as a whole. Time to buy.


Looks like the collapse in the Endo shareprice is the cause of all the irrational selling today in the spec pharma space.  Endo is yet another company that will have to sell off its assets to reduce its debt -- good news for companies like Aralez and Knight who are flush with cash.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities